Contrasting Crescent Biopharma (NASDAQ:CBIO) and Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and Crescent Biopharma (NASDAQ:CBIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Corcept Therapeutics and Crescent Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	3	3	1	2.50
Crescent Biopharma	1	0	5	3	3.11

Corcept Therapeutics presently has a consensus price target of $77.67, indicating a potential upside of 85.01%. Crescent Biopharma has a consensus price target of $28.00, indicating a potential upside of 44.93%. Given Corcept Therapeutics’ higher possible upside, research analysts clearly believe Corcept Therapeutics is more favorable than Crescent Biopharma.

Profitability

This table compares Corcept Therapeutics and Crescent Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	12.96%	15.19%	11.93%
Crescent Biopharma	N/A	-125.38%	-104.16%

Institutional and Insider Ownership

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 20.8% of Corcept Therapeutics shares are held by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Corcept Therapeutics and Crescent Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	5.86	$99.65 million	$0.82	51.20
Crescent Biopharma	$10.84 million	24.76	-$153.94 million	($14.21)	-1.36

Corcept Therapeutics has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Corcept Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Corcept Therapeutics beats Crescent Biopharma on 9 of the 14 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.